Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 12/20 | 0.75 |
| ▸ | KDM4A | O75164 | 12/20 | 0.75 |
| ▸ | HIF1AN | Q9NWT6 | 12/20 | 0.75 |
| ▸ | KDM2A | Q9Y2K7 | 12/20 | 0.75 |
| ▸ | KDM4D | Q6B0I6 | 11/20 | 0.75 |
| ▸ | KDM5B | Q9UGL1 | 10/20 | 0.47 |
| ▸ | KDM3B | Q7LBC6 | 10/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766387 | 0.86 | KDM6B (1.00) | KDM6BKDM4AHIF1ANKDM2AKDM4D | |
| SCHEMBL29351316 | 0.84 | KDM6B (0.73) | KDM6BKDM4AHIF1ANKDM2AKDM4D | |
| SCHEMBL10783573 | 0.77 | KDM6B (0.57) | KDM6BKDM4AHIF1ANKDM2AKDM4D | |
| SCHEMBL13525026 | 0.76 | KDM6B (0.61) | KDM6BKDM4AHIF1ANKDM2AKDM4D | |
| SCHEMBL4001347 | 0.75 | KDM6B (0.59) | KDM6BKDM4AHIF1ANKDM2AKDM4D | |
| SCHEMBL3577936 | 0.73 | KDM6B (0.58) | KDM6BKDM4AHIF1ANKDM2AKDM4D | |
| SCHEMBL2072718 | 0.72 | KDM6B (0.56) | KDM6BKDM4AHIF1ANKDM2AKDM4D | |
| SCHEMBL2713726 | 0.72 | KDM6B (0.56) | KDM6BKDM4AHIF1ANKDM2AKDM4D | |
| SCHEMBL19725083 | 0.72 | KDM6B (0.56) | KDM6BKDM4AHIF1ANKDM2AKDM4D | |
| SCHEMBL16466339 | 0.72 | KDM6B (0.56) | KDM6BKDM4AHIF1ANKDM2AKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655340-B1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| EP-2655340-B1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| US-8901147-B2 | Bi-heteroaryl compounds as Vps34 inhibitors | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8901147-B2 | Bi-heteroaryl compounds as Vps34 inhibitors | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8901147-B2 | Bi-heteroaryl compounds as Vps34 inhibitors | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20130338159-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| EP-2655340-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | Novartis AG (CH) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085815-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085815-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | VPS35, VPS26B, VPS26A | KDM6B 2422/4885KDM4A 1684/4885HIF1AN 1002/4885 |
| US-20130338159-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | VPS35, VPS26B, VPS26A | KDM6B 2429/4885KDM4A 1662/4885HIF1AN 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.